Characteristics and outcomes in atorvastatin therapy for chronic subdural hematoma: a national, observational real-world study in China, 2019–2024

作者：Tao Liu, Zhihao Zhao, Jiao Wang, Xiaoying Chen, Jinhao Huang, Weiwei Jiang, Yun-hu Yu, Xide Zhu, Richard C. Wang, Kun Lin, Qin Hu, Baixiang Peng, Guohe Zhang, Zhiyong Liu, Wei-Liang Chen, Jun Shen, Baozhi Chen, Shengjie Li, Mingqi Liu, Wanqiang Su, Wanhai Ding, Chun‐Hua Hang, Wenhua Fang, Feilong Yang, Rui Zhu, Wai Sang Poon, Jianning Zhang, Rongcai Jiang, Craig S. Anderson · 发表于：The Lancet Regional Health - Western Pacific · 年份：2025 · DOI：10.1016/j.lanwpc.2025.101688 · 被引用次数：2 · 研究领域：Neurosurgical Procedures and Complications、Intracerebral and Subarachnoid Hemorrhage Research、Traumatic Brain Injury and Neurovascular Disturbances

Background: The incidence of chronic subdural hematoma (cSDH) is increasing in the aging population worldwide, where the success of conventional surgical decompression is complicated by high rates of complications and recurrence. The anti-inflammatory properties of atorvastatin make it an attractive, low-cost, and safe medical approach, but limited evidence exists regarding its clinical benefit in cSDH. We aim to evaluate temporal trends, disease characteristics, and clinical outcomes associated with atorvastatin treatment for cSDH in real-world settings in China. Methods: This was a multicenter registry study of the Chronic Subdural Hematoma (MR-CSDH) in China. Adults received either 20 mg of atorvastatin or not daily for 8 weeks and were followed up for an additional 6 months at 61 medical centers between November 1, 2019 and October 30, 2024. The primary outcome was good functional outcome defined by modified Rankin scale scores of 0-3 at 6 months. Secondary outcomes included good clinical outcomes and recurrence at 3 months, mortality and recurrent SDH at 6 months, healthcare costs, suspected statin-related adverse events, and length of hospital stay. Logistic regression and propensity score matching (PSM) were used for analysis. The trial was registered with Chinese Clinical Trial Registry, identifier ChiCTR2200057179. Findings: A total of 2422 patients were included (mean [SD] age: 70.3 [14.5] years; 453 [18.7%] female), of whom 1777 (73.4%) received atorvastatin therap...